Biotech · Private company · Little Rock, AR, US
InterveXion Therapeutics, LLC
Track this companyFree. Adds InterveXion Therapeutics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- HaloperidolPhase 2 · Methamphetamine Intoxication (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
- IXT-m200Phase 2 · Methamphetamine-dependenceClinicalTrials.gov · fetched Nov 12, 2026
- IXT-m200Phase 2 · Methamphetamine Intoxication (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
- LorazepamPhase 2 · Methamphetamine Intoxication (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
- IXT-m200Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200PHASE2 · TERMINATED · started Jun 9, 2022ClinicalTrials.gov NCT05034874 · fetched Nov 12, 2026
- Safety, Tolerability, and Pharmacokinetics of IXT-m200PHASE1 · COMPLETED · started Oct 25, 2021ClinicalTrials.gov NCT05027451 · fetched Nov 12, 2026
- Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine OverdosePHASE2 · TERMINATED · started Jun 30, 2021ClinicalTrials.gov NCT04715230 · fetched Nov 12, 2026
- Study of Antibody for Methamphetamine Outpatient TherapyPHASE1_PHASE2 · COMPLETED · started May 3, 2018ClinicalTrials.gov NCT03336866 · fetched Nov 12, 2026
NIH awards1
- IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorderFiscal year 2024 · $4.3MNIH RePORTER 5U01DA056240-03 · fetched Nov 12, 2026